Tagrisso suitable for patients with disease progression to CNS metastases, data shows

Tagrisso (osimertinib), the potential new standard-of-care for locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), also shows efficacy in patients with disease progression to central nervous system (CNS) metastases, according to new evidence reported at ASCO 2017.

The findings from the Phase III AURA3 trial showed that the AstraZeneca (LSE: AZN) drug doubled the length of time patients with CNS metastases lived without disease worsening or death versus chemotherapy, with figures of 11.7 months compared to 5.6 months.

Marina-Chiara Garassino, from the Thoracic Oncology Unit, Medical Oncology Department Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, said: “The results of osimertinib in patients with CNS metastases are consistent with what has already been reported in the overall AURA3 population.